Description
Monlumax 200Mg - Anti-COVID Generic Drug Molnupiravir
ACME branded generic version of Molnupiravir will be marketed by Monlumax 200 (Molnupiravir 200 mg INN) Developed by the US based pharma Merck & Ridgeback
Additional Information
Molnupiravir is the
world’s first oral pill to treat symptomatic COVID-19 which was approved
by the UK’s Medicines and Healthcare products Regulatory Agency on 4
November 2021. Molnupiravir is originally developed by the US based
pharma major Merck, Sharp & Dohme (MSD) and Ridgeback
Biotherapeutics.